Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
This is a shot in the arm for the vaccine manufacturers
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
It is used for the treatment of advanced colorectal and gastric cancer
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
Nelarabine is in a class of medications called antimetabolites
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Subscribe To Our Newsletter & Stay Updated
